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P.J. M E I E R-A BT
Science and innovation have always been important pillars of the social, cultural and economic development of Switzerland. Th is is especially true for biomedical research, a fi eld in which this small country has a long and successful tradition. Indeed, it is probably not an overstatement to say that Switzerland's current wealth and high standard of living would not have been possible without a continuous fl ow of biomedical discoveries and new life science technologies, together with their successful translation into medical practice.
Th is progress is surprising for such a small country as Switzerland. It is based on several factors including the stable and free political system, the periodic appearance of outstanding intellectual personalities and the creation of an increasing number of academic institutions over the past few centuries.
Some of the most creative and infl uential Swiss personalities to push forward biomedical research are featured in this issue of the Karger Gazette. Certainly many other individuals and innovations of equal importance could have been added, but the examples selected highlight a broad spectrum of Swiss contributions. Included are pioneering molecular studies (the discovery of DNA), groundbreaking progress in psychiatry (the concept of 'schizophrenia'), the development of surgical techniques and tools, innovative synthetic chemistry (the industrial synthesis of vitamin C), and the fi rst steps into the area of nutritional health with the propagation of Bircher muesli. Th is issue also ventures into more controversial territory with a look at Ita Wegman, who founded anthroposophical medicine in Switzerland. Although the scientifi c basis of this system of healthcare remains a matter of debate, complementary and alternative medicine has become very popular and remains a huge challenge for the rational application of the principles of evidenced-based medicine.
It is important to remember that these outstanding individuals did not exist in splendid isolation. Th ey were immersed in a culture that had for centuries stimulated research, through the consecutive foundation of fi ve universities (Basel, Bern, Geneva, Lausanne, Zürich) and two Federal Schools of Technology (ETH Zürich and Lausanne). Th e oldest of these is the University of Basel, which was founded by Papal decree in 1460 and is celebrating its 550th anniversary this year.
During its long existence the University of Basel has hosted many infl uential and visionary thinkers. Among those to walk the halls of the university are Erasmus, the humanist and theologian, the famous Bernoulli family of mathematicians, Friedrich Nietzsche, the philosopher, and Carl Gustav Jung, the psychiatrist. Today, the region of Basel is one of the world's leading life science centers, hosting the headquarters of pharmaceutical giants Novartis and Roche alongside numerous other drug companies and research institutions. In this, Basel has profi ted greatly from its strategic location at the point where the borders of France and Germany meet Switzerland.
Although somewhat younger of age, the other Swiss universities also declared biomedical sciences as one of their priorities and gained international reputations in various research fi elds. Today, attempts are being made to bundle and coordinate tertiary education and sciences within a nationwide network of complementary research groups and strong interactions between the diff erent Swiss universities.1
Th ese developments refl ect a trend in modern science away from individual researchers and towards research teams. Indeed, it is a debated issue whether the future of scientifi c research will be driven by outstanding single individuals, as in the past, or by teams and centers of closely interacting researchers and organizations. But it is certain that the times of Friedrich Miescher, who made his breakthrough discovery of DNA working alone in a converted kitchen, are behind us.
The Power of We
Great ideas springing from the great minds of singularly creative individuals will always remain a force of the utmost potency, These developments refl ect a trend in Th modern science away from individual researchers and towards research teams. Indeed, it is a debated issue whether the future of scientifi c research will fi be driven by outstanding single individuals, as in the past, or by teams and centers of closely interacting researchers and organizations. But it is certain that the times of Friedrich Miescher, who made his breakthrough discovery of DNA working alone in a converted kitchen, are behind us.
The P Power T of We Great ideas springing from the great minds of singularly creative individuals will always remain a force of the utmost potency, ; my whole career as a gerontolog ist was motiva ted by the questio n of whethe r we can learn anythi ng about the aging process by studyin g age-rel ated diseases in animal s and human s. When we look at age-rel ated disease s, it may be worthw hile to disting uish betwee n those that are a primar y manife station of senesce nce, such as Werne r's disease or Hutchi nson-G ilford syndro me, and those which represe nt second ary phenom ena, suffere d as a conseq uence of reachin g old
T h e
From the above-mentio ned rectang ular pattern of the human surviva l curve one can deduce that, based on an individ -ual fixed genetic backgr ound, modifi cation of environ mental factors is presen tly the only tool to achieve 'health y aging'.
The concep t of pleiotro pic antago nism is relevan t when consid ering age-rel ated disease s. It is based on the observ ation that genes that are benefic ial early in life may play a detrim ental role later on when they are express ed at sites other than their original positio n (pleiotr opy). For instanc e, some genes allow for calcific ation of bones (osteoc alcin and bone sialopr otein), making them stronge r and improv ing fightin g and fleeing capacit y, but they acquire negative, antago nistic effects later in life if they are express ed elsewh ere, leading , for examp le, to calcifie d atheros clerotic lesions. Theref ore, the disease s of aging may be the price we pay for the vigor of youth. It should also be reiterat ed that the natura l rules underly ing the develop ment of age-rel ated disease s are today skewed by the pace of change in human lifestyl e (cultural evoluti on), which is far too fast for genetic adapta tion to keep up with. Thus, we live under 21st century conditi ons with a pre-sto ne age genom e. In the words of the evoluti onary biologi sts Nesse and Williams, 'The price of not being eaten by a lion at the age of 30 may be a heart attack at 80' [4] .
Anti-A ging and Scienc e Kitsch
Often, geronto logists workin g in basic re- age becaus e our cultura l evoluti on by far outpac es biologi cal evoluti on. Howev er, I think such a distinc tion betwee n 'pure' senescen ce and patholo gical age-ass ociated process es is a rather academ ic issue, raising unnece ssary barrier s betwee n basic and applied geronto logical researc h that may impair the crucial and benefic ial dialogue betwee n various discipl ines. In addition, we should not forget that geronto logy in a broade r sense encom passes many fields outside of biology , the aging society represe nting one of the most import ant socioec onomic problem s facing not only the develop ed world, but increas ingly also the less develop ed countr ies.
Age-Re lated Diseas es: The Price for the Vigor of Youth
In 1900, the mean life expect ancy in Central Europe and the USA was about 49 years. Since that time, life expecta ncy has increas ed more than in the 10,000 years before. This has been due to advanc es in medici ne and hygien e, as well as improv ements in socioec onomic conditi ons.
Althou gh the mean life expecta ncy has increas ed, this has been associa ted with a rather constan t value for maxim ally attainable age. When plotted on a graph, this leads to a 'rectan gulariz ation' of the human surviva l curve (Fig. 1, page 2 ). This observ ation is one of many indicat ions that the aging process is govern ed by both genetic and environ mental factors . Discus sing this issue in depth is beyond the scope of this article. Suffice it to mentio n that different species exhibit differe nt maxim al lifespa ns that show a signific ant correlation with their capacit y to repair DNA damag e. ments in s Althou gh gh the mean life increas ed, th this has been associa ted with a rather consttan t value for maxim ally attainable age. W When plotted on a graph, this leads to a 'r 'rectan gulariz ation' of the human surviva val curve (Fig. 1, page 2 ). This observ ation n is one of many indicat ions that the aging pr process is govern ed by both genetic and en environ mental factors . Discus sing this issu ue in depth is beyond the scope of this articl cle. Suffice it to mentio n that different speci cies exhibit differe nt maxim al lifespa ns that show a signific ant correlah t show ignifica n rrelation with their capacit y to repair DNA damag e. 
G a z e tt e
Ka rg er
When we were first approach ed by the translators of Andreas Vesalius' ground-b reaking atlas of anatomy De humani corporis fabrica, I was not aware of how much the publicatio n of this English translatio n from the original Latin would influence our publishin g house and me personall y. I have always been fascinated by the Renaissan ce and its art and architecture, but I now fully appreciat e the enormou s impact the Renaissan ce invention of the printing press had on the rise of modern science and medicine -and how much this resembles the profound effect that the dawn of the digital age has had on our own times. Now, after two years of intensive and challenging work, the first comprehe nsive and annotated translatio n into English of both editions of the original Fabrica has just been published by Karger -a modern and user-frien dly edition with a total of over 1,400 pages in A3 format, with greatly enhanced illustratio ns, and an impressiv e weight of 14 kg.
The articles in this issue of the Karger Gazette introduce you to Vesalius as a pioneer of modern anatomy and also go beyond to look at the role of art and illustratio n in a medical and historical context. I also invite you to visit our special website www.vesa lius-fabric a.com where you will find some more interestin g stories about Vesalius, his times and his work as well as backgrou nd informati on on the production of the New Fabrica.
With this excursion into the beginnin gs of modern medicine and printing, I wish you enjoyable reading.
Gabriella Karger
Publishe r's Note
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This journal covers the most active and promising areas of current research in gynecology and obstetrics. Invited, well-referenced reviews by noted experts keep readers in touch with the general framework and direction of international study. Original papers report selected experimental and clinical investigations in all fields related to gynecology, obstetrics and reproduction. Short communications are published to allow immediate discussion of new data. The international and interdisciplinary character of this periodical provides an avenue to less accessible sources and to worldwide research for investigators and practitioners.
www.karger.com/goi
This highly respected and frequently cited journal is a prime source of information in the area of fetal and neonatal research. Original papers pre sent research on all aspects of neonatology, fetal medicine and developmental biology. These papers encompass both basic science and clinical research including randomised trials, observational studies and epidemiology. Basic science research covers molecular biology, molecular genetics, physiology, biochemistry and pharmacology in fetal and neonatal life. Papers reporting results of animal studies should be based upon hypotheses that relate to developmental processes or disorders in the human fetus or neonate.
www.karger.com/neo
‚Breast Care' is a peer-reviewed scientific journal that encompasses all aspects of breast biology. As an interdisciplinary journal, it includes manuscripts describing basic research, prevention, diagnosis, and treatment of both benign and malign diseases of the breast. In addition to presenting current developments in clinical research, it addresses broader topics in clinical practice by including articles that address legal, financial and economic issues of importance.
www.karger.com/brc
‚Developmental Neuroscience' is a multidisciplinary journal publishing papers covering all stages of invertebrate, vertebrate and human brain development. Emphasis is placed on publishing fundamental as well as translational studies that contribute to our understanding of mechanisms of normal development as well as genetic and environmental causes of abnormal brain development.
The journal thus provides valuable information for both physicians and biologists. To meet the rapidly expanding information needs of its readers, the journal combines original papers that report on progress and advances in developmental neuroscience with concise mini-reviews that provide a timely overview of key topics, new insights and ongoing controversies.
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The first journal to focus on the fetus as a patient, 'Fetal Diagnosis and Therapy' provides a wide range of biomedical specialists with a single source of reports encompassing the common discipline of fetal medicine. The journal comprehends sections such as Mini Reviews, where specific questions of clinical interest are addressed by internationally renowned experts in the field, or Images in Fetal Medicine, which aims at exploiting the huge amount of images that the practice of fetal medicine generates, with particular interest in documenting cases with multimodal imaging. 'Fetal Diagnosis and Therapy' offers a selection of peer-reviewed original research papers ranging in scope from basic and pathophysiologic investigations to clinical studies in fetal diagnosis and therapy.
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The essential resource for today's cytopathologist
Off ering an excellent balance of articles on both clinical cytology and cytopathology, Acta Cytologica furthers the understanding of cytopathologic processes and facilitates the translation of current research into clinical practice. As the offi cial journal of the International Academy of Cytology and affi liated to over 50 cytology societies around the world, Acta Cytologica evaluates new and existing diagnostic applications of scientifi c advances as well as their clinical correlation. Original papers, review articles, case reports and letters to the editor cover topics from diagnostic cytopathology, gynecologic and nongynecologic cytopathology to fi ne-needle aspiration, molecular techniques and diagnostic methodologies.
The perfect reference for practical use, Acta Cytologica addresses a multidisciplinary audience involved in the clinical practice of cytopathology, cell biology, oncology, interventional radiology, otorhinolaryngology, gastroenterology, urology, pulmonology and preventive medicine. 
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